Onvatilimab is a Monoclonal Antibody owned by ImmuNext, and is involved in 1 clinical trial, which is ongoing.

Onvatilimab (JNJ-61610588) targets V-region immunglobulin-containing suppressor of T cell activation (VISTA). VISTA is expressed primarily on hematopoietic cells and is regulated on myeloid antigen-presenting cells (APCs) and T cells. It targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth and checks disease progression.

The revenue for Onvatilimab is expected to reach a total of $100m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Onvatilimab NPV Report.

Onvatilimab was originated by Janssen Biotech and ImmuNext and is currently owned by ImmuNext. Curis is the other company associated in development or marketing of Onvatilimab.

Onvatilimab Overview

Onvatilimab (JNJ-61610588) is under development for the treatment of relapsed / refractory solid tumors including malignant mesothelioma, melanoma, non-small cell lung cancer, triple-negative breast cancer (TNBC).It is administered intravenously. VISTA is V-region immunglobulin-containing suppressor of T cell activation. It's extracellular domain shares homology to the B7 family ligand programmed cell death ligand 1 (PD-L1).

It was under development for the treatment of cancers such as non-small cell lung cancer, small cell lung cancer, head and neck cancer, pancreatic, colorectal, bladder cancer, and cervical cancers.

Curis Overview

Curis is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries.

The company reported revenues of (US Dollars) US$10.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 1.7% over FY2020. The operating loss of the company was US$41.2 million in FY2021, compared to an operating loss of US$24.9 million in FY2020. The net loss of the company was US$45.4 million in FY2021, compared to a net loss of US$29.9 million in FY2020. The company reported revenues of US$2.4 million for the second quarter ended June 2022, an increase of 16.3% over the previous quarter.

Quick View – Onvatilimab

Report Segments
  • Innovator
Drug Name
  • Onvatilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.